NCT02145143View on ClinicalTrials.gov

Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

May 20, 2014

Primary Completion Date

November 21, 2024

Study Completion Date

November 21, 2024

Conditions

Thyroid Carcinoma

Interventions

DRUG

Vemurafenib

DEVICE

serial 124I PET/CT

DRUG

thyrotropin alpha

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT02145143 - Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study | Biotech Hunter | Biotech Hunter